Member Info for Prion25

Bootnk

I agree my experience with Synairgen and Sareum Nice all for big Pharma and Gov I feel they want Genedrive to fail and pick up the tech next to nothing

For those expecting more this was a Phase 1a dose-escalation poster where the primary goals are safety and dose finding rather than definitive efficacy. So I asked Copilot AI to deep dive into the nuances out of interest.

Nuances that matter beyond the headline

Cardiac safety is meaningful but not definitive. Showing no severe cardiotoxicity at cumulative doses above conventional doxorubicin limits removes a major historical barrier for anthracycline use. This opens the possibility of higher effective payload exposure and novel combination regimens. The finding still requires larger patient numbers and longer follow-up to exclude late or rare cardiac effects.

Mechanism and patient selection nuance. The pre|CISION delivery approach releases payload via FAP biology in the tumour microenvironment. Clinical activity in tumours without tumor-cell FAP suggests a stromal bystander effect. That broadens potential indications but also complicates biomarker-driven patient selection strategies.

No MTD reached creates both opportunity and ambiguity. The absence of a tolerability ceiling suggests a wide therapeutic window but leaves dose selection for later trials uncertain. Optimal biological dose for efficacy may not be the highest tolerated dose.

Efficacy signals are encouraging in a rare orphan setting. Durable PFS in pretreated salivary gland cancer patients is notable because treatment options are limited. That signal can justify accelerated development in a niche indication while larger trials are planned.

Safety profile differences versus ADCs are early but promising. Reduced systemic toxicities compared with conventional doxorubicin and absence of ADC-like off-target payload release were highlighted, but Phase 1 numbers are insufficient to rule out uncommon or delayed class toxicities.

What to watch next

Phase Ib expansion data for salivary gland cancers due Q4 2025. Updated, larger-cohort efficacy and longer cardiac follow-up will materially change confidence in the signal.

TNBC cohort data expected in H1 2026. This will test activity in a larger, more competitive indication and affect partnership or licensing interest.

Randomized or controlled trials and combination studies. Evidence versus standard of care or combined with immunotherapy

Thanks BV

For tidying up my rushed version of the important and fantastic conclusions

just need the 1+ at the end minimal expression

conclusion faridoxorubicin (ava6000) is safe

and well-tolerated in both the q3w

and q2w dosing regimens with,

with preliminary evidence of

efficacy in patients with soft tissue

sarcomas (sts) and salivary gland

cancers (sgc) and no severe

cardiac toxicity. no mtd was

determined in the trial despite

dosing up to 385 mg/m2

(~4x conventional dose doxorubicin)

• faridoxorubicin treatment

demonstrates low rates of

severe toxicities that are

associated with

conventional doxorubicin

•confirmed responses

were observed in patients

with stromal only

expression of fap with

sgc and tumor cell

expression of fap in sts

• in the cohort of sgc patients, median

pfs has not yet been reached. the

median follow up is estimated at 51

weeks (using the reverse ****** meier

method)

• the median tumor to plasma ratio of

released doxorubicin is 100:1 and

doxorubicin concentration in the tumor

demonstrates a strong dose response.

effective cleavage and concentration in

the tumor is evident at all levels of fap

expression including patients with

tumors demonstrating minimal 1+

expression

Cost benefits ,,black lives matter

PSE will be considered as a as a reflex test given test given a 4-12 PSA and abnormal DRE But at what cost to NHS ? The reflex test is under consideration seems to me they have worked out the cost benefits of PSE

Not too concerned gas turbine tech and Ceres are chasing different segments of the power market

Gas turbine usually centralised large scale centralised power distribution with high emissions

Ceres smaller scale distribution high efficiency lower emissions our niche are data centres has already been discussed GLA

Astounding news

Blinded by the light

If Dr Helen can galvanise the SP it will do wonders for my mental health . Great news

It is not a failure I postulate a big Koch up by the lab

Thanks Bewatchful

The shape of things to come

BNP Paribas focused on AI related investments

BNP Paribas increased holding ?

Thanks D-Geeman

Great Post very interesting and exciting revelation

From AI

Tiziana Life Sciences and the FOXP3 Nobel Prize Connection

The 2025 Nobel Prize in Physiology or Medicine was awarded to Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi for their groundbreaking discoveries around FOXP3⁺ regulatory T cells (Tregs)—a key mechanism in maintaining immune tolerance and preventing autoimmune disease2.

While Tiziana Life Sciences was not directly nominated or awarded, their lead therapeutic candidate, Foralumab, is deeply connected to this Nobel-recognized biology:

🔍 How Tiziana Ties In

Foralumab is a fully human anti-CD3 monoclonal antibody.

It has been shown to induce FOXP3⁺ Tregs when administered intranasally.

This mechanism aligns with the Nobel-winning research on immune regulation via FOXP3.

Tiziana has positioned Foralumab as a translational example of how FOXP3 biology can be harnessed to treat inflammatory and autoimmune conditions.

🧠 Why It Matters

The Nobel Prize spotlight on FOXP3⁺ Tregs validates the scientific foundation of Tiziana’s approach.

It could boost investor confidence and accelerate clinical interest in Foralumab.

Tiziana’s alignment with Nobel-recognized science places it at the forefront of next-generation of immunomodulatory therapies

Any further news ?

Https://presentations.investormeetcompany.com/investor-meet-company/ceres-power-holdings-plc-interim-results-7e41a2c88c0ffa211225664a?bmid=9cfd819affeb

Dying not according to the presentation .Near term commercialisation of SOFC alive and kicking

“We are continuing to position ourselves as key players in the electrolysis markets, building relationships with technology manufacturers, systems integrators and green hydrogen off-takers. With two exciting market opportunities now in front of us, addressing power first and hydrogen following, and benefiting from a mature and scalable single product approach, we are confident that we have the strategy to establish our technology as the industry standard for solid oxide.”

Ceres made giant global stride in a huge marketplace driven by power hungry AI data centres using their SOFC and providing green hydrogen for decarbonisation using SOEC unique technologies The future is definitely bright

Https://www.trinitydelta.org/research-notes/prowes-cirt-utility-in-guiding-treatment-decisions/

👍